BOCA RATON, Fla., Feb. 25, 2026 – Totaligent, Inc. ($TGNT), an emerging leader in intelligent business marketing data solutions, has announced a binding Letter of Intent (LOI) with GloMed Solutions Limited Liability Company, a Japanese distributor specializing in medical aesthetics and biologics. This strategic partnership aims to establish a joint venture that integrates Totaligent's recently acquired Aetherium Medical platform into GloMed's operations, while also providing Totaligent with a binding call option to fully acquire GloMed.
This collaboration positions Totaligent as a significant player in the rapidly evolving biologics and medical tourism sectors, paving the way for comprehensive ownership and enhanced global growth.
Aetherium Medical, founded by innovative entrepreneur Ivan Klarich, serves as a vital link between cutting-edge biotech firms—especially those utilizing AI-enhanced discovery—and global patients through ethical medical tourism channels and a dual-track regulatory pathway. The platform adeptly combines specialized logistics, turnkey commercialization, and strong ethical governance to circumvent traditional regulatory hurdles, such as protracted FDA approval processes, while generating immediate revenue in established APAC markets, including Japan.
GloMed, under the leadership of CEO Don Heath, boasts a robust portfolio of medical aesthetics and biologics products, distributed via a proprietary network of over 20 key opinion leaders and specialty clinics across high-growth APAC markets. With approximate annual revenue of $10 million and $1 million in free cash flow, GloMed represents a valuable target for Totaligent's growth strategy.
The binding LOI, executed on February 22, 2026, includes an exclusivity period during which GloMed and Don Heath will exclusively negotiate with Totaligent regarding the joint venture and any potential sale or transfer of GloMed.
The joint venture is expected to close in about four weeks, around March 22, 2026, subject to conditions including the exercise of the call option, acquisition closing contingent on a PCAOB-compliant audit, and any necessary regulatory or shareholder approvals.
To facilitate operations, the joint venture and potential acquisition will be supported by Totaligent's active Standby Equity Purchase Agreement, which provides an equity line of credit to cover cash requirements and ongoing needs.
This collaboration and prospective acquisition leverage Totaligent's targeted marketing capabilities to engage AI-biotech innovators and APAC clinics, expediting the commercialization of advanced biologics.
The global biologics market is forecasted to reach approximately $650 billion by 2030, driven by advancements in AI-enabled therapies for cancer, autoimmune disorders, and genetic diseases. Simultaneously, the medical tourism market is set for substantial growth, with estimates ranging from $56 billion in 2026 to over $250 billion by 2034, fueled by cost-effective and high-quality access in APAC destinations.
Edward C. DeFeudis, CEO of Totaligent, remarked, “This binding LOI with GloMed, along with the call option for full acquisition, marks a transformative milestone in our shift towards high-growth opportunities in AI-biotech and global access. By establishing the joint venture and positioning for complete ownership of GloMed’s extensive network and revenue stream, we can mitigate risks and accelerate the delivery of innovative therapies for patients worldwide. We are eager to collaborate with Don Heath and Ivan Klarich to navigate this trillion-dollar market inflection point through strategic consolidation.”
The transaction remains subject to negotiations, execution of definitive agreements, satisfactory due diligence, board approvals, completion of a PCAOB-compliant audit (if required), and other standard conditions. There is no assurance that definitive agreements will be finalized or that the proposed transaction will be completed.
For more information about Totaligent, Inc. ($TGNT), please visit www.totaligent.com. For more details about Aetherium Medical, visit www.aetheriummedical.com.